SkinHealth Systems Inc. (SKIN): Results of Operations and Financial Condition
SkinHealth Systems Inc. (SKIN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex991-2026q2xearnings.htm EX-99.1 Document Exhibit 99.1 SkinHealth Systems Reports Second Quarter 2026 Financial Results Long Beach, Calif., August 6, 2026 – SkinHealth Systems Inc. (NASDAQ: SKIN) (“SkinHealth Systems” or the "Company"), home to flagship brand Hydrafaci
How this was made
The 30-second read
Why it matters
Traders can update expectations using the revised Q3 and FY 2026 net sales and adjusted EBITDA ranges, and assess whether margin gains offset ongoing sales pressure.
Market read
The guidance ranges and the mix of sales decline versus margin/EBITDA improvement are the actionable elements for near-term positioning in SKIN.
What to watch
The filing attributes gross margin improvement to prior-year cost effects and notes distributor transitions in Australia/New Zealand and China, which may affect comparability and future sell-through.
Background
This is an SEC 8-K (Item 2.02) with Q2 2026 financial results and revised 2026 guidance for SkinHealth Systems, maker of Hydrafacial.
Ticker impact
SkinHealth Systems reported Q2 2026 results and revised 2026 guidance, including Q3 net sales $65-$70M and adjusted EBITDA $5-$7M.
Likely choppy reaction: upside support from higher adjusted EBITDA and gross margin, offset by weaker delivery systems and lower net sales.
The filing discloses both a sales decline and improved gross margin/adjusted EBITDA, plus explicit revised Q3 and FY 2026 ranges that traders can reprice immediately.
Market effects
Provides a read-through for consumer/beauty device and recurring consumables models, highlighting sensitivity to delivery systems demand.
Regional net sales show weakness across Americas, APAC, and EMEA, with distributor transitions noted for Australia/New Zealand and China.
Limited broader market impact; primarily company-specific repricing around guidance and installed-base productivity.
Counterpoint
The adjusted EBITDA outperformance may be partly cost-driven and could fade if delivery systems placements remain weak.
Key entities
- companySkinHealth Systems Inc.
NASDAQ-listed company reporting Q2 2026 results and revised 2026 guidance.
- product/brandHydrafacial
Flagship brand referenced as central to the company’s franchise strategy.
- executivePedro Malha
CEO quoted on sales pressure, margin improvement, and strategic priorities.

